Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women
View abstract on PubMed
Summary
This summary is machine-generated.Long-term oral bisphosphonate use in older women is linked to a higher risk of unusual femur fractures. However, the overall incidence of these specific fractures remains low.
Area Of Science
- Geriatric Medicine
- Pharmacology
- Orthopedic Surgery
Background
- Osteoporosis poses significant health risks, with oral bisphosphonates being a primary treatment.
- Long-term bisphosphonate therapy raises concerns regarding suppressed bone remodeling and atypical fractures.
Purpose Of The Study
- To investigate the association between prolonged bisphosphonate therapy and the risk of subtrochanteric or femoral shaft fractures.
Main Methods
- A population-based, nested case-control study involving women aged 68+ in Ontario, Canada.
- Analysis of bisphosphonate use duration and its correlation with subtrochanteric/femoral shaft fractures versus typical osteoporotic fractures.
Main Results
- Treatment with oral bisphosphonates for over 5 years showed an increased risk of subtrochanteric/femoral shaft fractures (aOR 2.74).
- Conversely, prolonged bisphosphonate therapy was associated with a reduced risk of typical osteoporotic fractures (aOR 0.76).
- The absolute risk of these atypical fractures remained low, even with extended treatment.
Conclusions
- Extended bisphosphonate therapy (over 5 years) in older women is associated with a higher risk of subtrochanteric and femoral shaft fractures.
- Despite the increased risk, the absolute risk of these specific fractures is low.
- This highlights a potential trade-off between preventing typical osteoporosis-related fractures and the risk of atypical ones with long-term use.